Metabolic and non-metabolic factors determining troglitazone hepatotoxicity: a review.
about
Vitamin E, antioxidant and nothing moreEffect of chronic treatment with Rosiglitazone on Leydig cell steroidogenesis in rats: in vivo and ex vivo studiesReal-time monitoring of metabolic function in liver-on-chip microdevices tracks the dynamics of mitochondrial dysfunctionAre animal models predictive for humans?Hepatobiliary disposition of troglitazone and metabolites in rat and human sandwich-cultured hepatocytes: use of Monte Carlo simulations to assess the impact of changes in biliary excretion on troglitazone sulfate accumulation.Troglitazone induces cytotoxicity in part by promoting the degradation of peroxisome proliferator-activated receptor γ co-activator-1α protein.Inhibition of monoacylglycerol lipase by troglitazone, N-arachidonoyl dopamine and the irreversible inhibitor JZL184: comparison of two different assays.Exploring BSEP inhibition-mediated toxicity with a mechanistic model of drug-induced liver injury.Differential disposition of chenodeoxycholic acid versus taurocholic acid in response to acute troglitazone exposure in rat hepatocytes.Pleiotropic effects of glitazones: a double edge sword?Downregulation of the proinflammatory state of circulating mononuclear cells by short-term treatment with pioglitazone in patients with type 2 diabetes mellitus and coronary artery diseaseIncreased insulin sensitivity and reduced micro and macro vascular disease induced by 2-deoxy-D-glucose during metabolic syndrome in obese JCR: LA-cp rats.Prediction of drug-induced intrahepatic cholestasis: in vitro screening and QSAR analysis of drugs inhibiting the human bile salt export pump.Drug metabolite profiling and elucidation of drug-induced hepatotoxicity.Endogenous bile acid disposition in rat and human sandwich-cultured hepatocytes.Role of biotransformation in 3-(3,5-dichlorophenyl)-2,4-thiazolidinedione-induced hepatotoxicity in Fischer 344 rats.Peroxisome proliferator-activated receptor ligand MCC-555 suppresses intestinal polyps in ApcMin/+ mice via extracellular signal-regulated kinase and peroxisome proliferator-activated receptor-dependent pathwaysRecent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME.Technical pitfalls and improvements for high-speed screening and QSAR analysis to predict inhibitors of the human bile salt export pump (ABCB11/BSEP).Inflammatory stress and idiosyncratic hepatotoxicity: hints from animal models.Rapid LC-MS drug metabolite profiling using microsomal enzyme bioreactors in a parallel processing format.Metabolic bioactivation and drug-related adverse effects: current status and future directions from a pharmaceutical research perspective.Role of the bile salt export pump, BSEP, in acquired forms of cholestasis.Transcriptional, Functional, and Mechanistic Comparisons of Stem Cell-Derived Hepatocytes, HepaRG Cells, and Three-Dimensional Human Hepatocyte Spheroids as Predictive In Vitro Systems for Drug-Induced Liver Injury.Metabolites in safety testing.Genetic variations of bile salt transporters as predisposing factors for drug-induced cholestasis, intrahepatic cholestasis of pregnancy and therapeutic response of viral hepatitis.Animal models of idiosyncratic drug-induced liver injury--current status.Transporter-mediated drug-drug interactions with oral antidiabetic drugs.Level of dietary energy and 2,4-thiazolidinedione alter molecular and systemic biomarkers of inflammation and liver function in Holstein cows.Current challenges and controversies in drug-induced liver injury.Cytotoxic effect of different statins and thiazolidinediones on malignant glioma cells.High endoplasmic reticulum activity renders multiple myeloma cells hypersensitive to mitochondrial inhibitors.Efficient assessment of the utility of immortalized Fa2N-4 cells for cytochrome P450 (CYP) induction studies using multiplex quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR) and substrate cassette methodologies.The mitochondrial superoxide/thioredoxin-2/Ask1 signaling pathway is critically involved in troglitazone-induced cell injury to human hepatocytes.Quantification of Drug-Induced Inhibition of Canalicular Cholyl-l-Lysyl-Fluorescein Excretion From Hepatocytes by High Content Cell Imaging.Cytotoxicity of thiazolidinedione-, oxazolidinedione- and pyrrolidinedione-ring containing compounds in HepG2 cells.Study of the Effects of ATP Suppliers and Thiol Reductants on Toxicity of Pioglitazone in Isolated Rat Liver Mitochondria.A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Computational chemistry approach for the early detection of drug-induced idiosyncratic liver toxicity.Metabolism-guided drug design
P2860
Q24676043-7A8F1917-784A-4B67-8D41-1ECC5DD1A144Q28575457-96394644-30BC-4F3D-8121-20B3EA949557Q28834338-F865CC02-D04D-422D-B601-0E676AD2DB8DQ30374372-3DEC9704-7063-4C28-A124-C5361E13F530Q33574904-023C42B6-7EF1-4CB4-BD16-6A70241C9F20Q34356092-2FA4FD21-BE6F-4535-8A11-484C29F1DFC1Q34442314-A0E4AA2C-2CF8-43A1-9DEE-D3E2C623CD0DQ34471194-65FAF258-E874-4804-8122-D937CBD29EA8Q34701840-68C9F39B-CDCB-4837-9050-1A8FB10F33C9Q35025858-8EB5F2BC-D5AB-4049-9834-57A799250CE5Q35130917-1A64315E-8AFA-44F4-933E-0A53EC7BDAB3Q36052731-9F4E13A7-DAAE-445F-9CF6-98EA1298827BQ36689081-C1456850-8A03-4649-93A0-4BC5727BF2A2Q36835826-739A8385-71C5-4BF6-81C7-504414752230Q36919924-212111D4-446A-4CEA-B38A-29A7CA9D5B15Q36943606-6CE712BE-C97C-4AE8-85A7-F013D425F176Q37001526-65B245C9-9955-426D-9D61-9A0229C54F31Q37121662-066B8B9D-FB95-4364-9AC5-F6B0EBC2785FQ37378080-D80D71E7-09CF-4592-B4B5-313008F12799Q37391731-52CDB28D-D3E3-46DF-AFAA-93B5E2F39AC6Q37480700-9A794469-A0E8-4686-8CD8-D36235422D7CQ37638755-4DBBAB43-5E96-4C15-ADFE-4BD7B19DD839Q37661069-2BDDB9DA-2935-4643-9284-62D15A8F3C1CQ37718523-6CBEBFEA-A093-4CD1-BA1A-73BBC6E6E81DQ37810131-24125F4A-8456-48A3-B770-5CC4E8F47CBBQ37841614-DE8EDB5B-DEA3-4978-9728-4F339A655499Q37897219-AD9E34D1-047E-49DF-98A6-010636D41CC6Q38168993-D3A6AAC1-0F32-4B62-931F-3CDE96323FC4Q38637927-3E1BB02C-C35C-4208-803F-49642D133400Q39523252-35EDBF95-1F06-4DD0-98D8-2FC6435C9855Q39625491-247B5C90-6FD1-4B1A-9B5F-54DEC7A5A755Q39795457-56B67C1D-ED16-4DA5-95B7-AB0FE14E98C7Q39920320-8F7B7433-85C7-41BC-8CB1-C64A8EE531D7Q40059036-1EA32EB6-3684-4B36-A5D4-9F1BBAD3775BQ40684311-BDF8D30B-A65C-4E03-B795-2DF9C8DE28EAQ41451544-9D6F99C5-E700-4706-B281-CFE581D8B9BCQ42275225-B8702D73-8ADC-4C80-B8F6-38CCB21DEB46Q42709815-D4B6CD43-83D8-4941-BC43-F6888FD5A42DQ45965228-E418C850-39D5-4FF3-87F2-EE0C4ABBE2D3Q56115898-77F9C942-BA73-4561-82D7-B4FF4DB17DAC
P2860
Metabolic and non-metabolic factors determining troglitazone hepatotoxicity: a review.
description
2006 nî lūn-bûn
@nan
2006 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Metabolic and non-metabolic factors determining troglitazone hepatotoxicity: a review.
@ast
Metabolic and non-metabolic factors determining troglitazone hepatotoxicity: a review.
@en
Metabolic and non-metabolic factors determining troglitazone hepatotoxicity: a review.
@nl
type
label
Metabolic and non-metabolic factors determining troglitazone hepatotoxicity: a review.
@ast
Metabolic and non-metabolic factors determining troglitazone hepatotoxicity: a review.
@en
Metabolic and non-metabolic factors determining troglitazone hepatotoxicity: a review.
@nl
prefLabel
Metabolic and non-metabolic factors determining troglitazone hepatotoxicity: a review.
@ast
Metabolic and non-metabolic factors determining troglitazone hepatotoxicity: a review.
@en
Metabolic and non-metabolic factors determining troglitazone hepatotoxicity: a review.
@nl
P356
P1476
Metabolic and non-metabolic factors determining troglitazone hepatotoxicity: a review.
@en
P2093
Yasuhiro Masubuchi
P304
P356
10.2133/DMPK.21.347
P577
2006-10-01T00:00:00Z